Translation
Jun 29, 2018
| Name of listed company: |
|
Chugai Pharmaceutical Co., Ltd. |
| Code number: |
4519 (1st Section of Tokyo Stock Exchange) |
| Head office: |
1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo |
| President & CEO: |
Tatsuro Kosaka |
| Inquiries to: |
Masahiko Uchida, General Manager,
Corporate Communications Dept. |
| |
Tel:+81-(0)3-3273-0881 |
Announcement of an Appeal against Chugai in Patent Infringement Lawsuit
Chugai Pharmaceutical Co., Ltd. announced today that it received a petition of appeal from the Intellectual Property High Court. The appeal was filed by Baxalta as of May 10, 2018, against the following judgment rendered by the Tokyo District Court on March 28, 2018.
- History
| Judgment (Favorable ruling for Chugai) |
March 28, 2018 |
| Service of appeal |
June 29, 2018 |
- Background for the Action
In the original trial, it was alleged by Baxalta that Chugai’s drug for treatment of hemophilia A, HEMLIBRA® (generic name: emicizumab), infringed Baxalta’s patent (patent number 4313531) and thus it filed for an injunction against manufacture, usage, transfer, exportation, and offer of any transfer regarding HEMLIBRA, and requested cessation. With regard to this action, Tokyo District Court rendered a decision in favor of Chugai's claim. Given this ruling, Baxalta appealed to the Intellectual Property High Court.
- Party Who Filed the Appeal
| (1) Name: |
Baxalta Incorporated
Baxalta GmbH |
| (2) Address: |
1200 Lakeside Drive Bannockburn, IL 60015, USA
Thurganerstrasse 130 Glattpark Opfikon 8152, Switzerland |
- Prospects
Chugai is confident that HEMLIBRA does not infringe Baxalta’s patent as so rendered by the District Court, and intends to continue pursuing its defense at the appellate court. Therefore no changes are expected in Chugai’s financial prospects.
Trademarks used or mentioned in this release are protected by law.
Contact:
For Media
Chugai Pharmaceutical Co., Ltd.
Media Relations Group, Corporate Communications Dept.,
Tomoko Shimizu
Tel: +81-3-3273-0881
E-mail: pr@chugai-pharm.co.jp
For Investors
Chugai Pharmaceutical Co., Ltd.
Investor Relations Group, Corporate Communications Dept.,
Toshiya Sasai
Tel: +81-3-3273-0554
E-mail: ir@chugai-pharm.co.jp
